TrialThe Journal of dermatology2019

Twenty-four-week interim analysis from a phase 3 open-label trial of adalimumab in Japanese patients with moderate to severe hidradenitis suppurativa.

Akimichi Morita et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.